SUPPLEMENTARY MATERIALS: Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, double-blinded, randomized, phase 3 POETYK PSO-2 trial
Published: 29 September 2022| Version 2 | DOI: 10.17632/vcfxdvhfw3.2
Contributor:
Bruce StroberDescription
Supplementary materials for the publication of Strober B. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, double-blinded, randomized, phase 3 POETYK PSO-2 trial. J Am Acad Dermatol 2022.
Files
Categories
Clinical Trial, Skin Disease, Psoriasis